Back to the main directory
EarningsReview / Equity
- Focus on the long game by BNP Paribas Exane
- FSN E-Commerce Ventures (NYKAA IN) by HSBC
- Defending its turf by BNP Paribas Exane
- STM and Legal set to accelerate by BNP Paribas Exane
- A Valentine''s Day surprise? We still see top line upside. by BNP Paribas Exane
- Ready to bounce by BNP Paribas Exane
- No turnaround in sight by BNP Paribas Exane
- Mixed results/guide but stellar 2022 growth ahead by BNP Paribas Exane
- Maisons de retraite : que peuvent faire les investisseurs ISR à présent ? by Oddo BHF
- Multiconsult - Buy/NOK 180: Solid outlook in growing market by Nordea
- INVEST SECURITIES - Unibail-Rodamco-Westfield : Un titre attractif malgré une visibilité perfectible - ACHAT, OC 83€ by Invest Securities
- INVEST SECURITIES - Valeo : Pas facile à digérer mais « tout va bien se passer » ! - ACHAT , OC 35€ (vs 40€) by Invest Securities
- WOOD Daily: Mytilineos (stays BUY), LTS PW, BVB RO, MNOD LI, ALRS RM, 4IG HB, TELEC CP, RO macro, DIGI RO by Wood and Company
- Nexi Spa (NEXI IM) by HSBC
- EQUITA SIM: BUZZI UNICEM (BUY; Unchanged): FY21 Preliminary Results by Equita Sim
- Itaú BBA on Multiplan: 4Q21 Results – Soaring Rents by Itau
- Improving outlook by BNP Paribas Exane
- Sangfor (300454 CH) by HSBC
- 1Q 22 IMS: FY guidance unchanged by BNP Paribas Exane
- Shareholder returns here to stay, MandA back in play by BNP Paribas Exane
- Itaú BBA on Intercorp Financial Services: Hitting Key Indicators but Weak 4Q21 Results Overall by Itau
- Expectations reset as Austerlitz project postponed by BNP Paribas Exane
- Pricing power key to offset cost pressures by BNP Paribas Exane
- Questions, questions by BNP Paribas Exane
- Alligator Bioscience (Buy, TP: SEK3.00) - Well financed for the coming year(s) by DnB Markets